1. Home
  2. III vs ABOS Comparison

III vs ABOS Comparison

Compare III & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Information Services Group Inc.

III

Information Services Group Inc.

HOLD

Current Price

$4.27

Market Cap

197.1M

ML Signal

HOLD

Logo Acumen Pharmaceuticals Inc.

ABOS

Acumen Pharmaceuticals Inc.

HOLD

Current Price

$2.26

Market Cap

197.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
III
ABOS
Founded
2006
1996
Country
United States
United States
Employees
1500
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
197.1M
197.9M
IPO Year
2006
2021

Fundamental Metrics

Financial Performance
Metric
III
ABOS
Price
$4.27
$2.26
Analyst Decision
Buy
Strong Buy
Analyst Count
1
2
Target Price
$5.50
$8.00
AVG Volume (30 Days)
175.6K
353.9K
Earning Date
05-07-2026
05-12-2026
Dividend Yield
4.46%
N/A
EPS Growth
216.67
N/A
EPS
0.05
N/A
Revenue
$192,745,000.00
N/A
Revenue This Year
$3.85
N/A
Revenue Next Year
$4.34
N/A
P/E Ratio
$87.60
N/A
Revenue Growth
4.51
N/A
52 Week Low
$3.74
$1.19
52 Week High
$6.45
$3.60

Technical Indicators

Market Signals
Indicator
III
ABOS
Relative Strength Index (RSI) 57.06 47.48
Support Level $3.86 $2.13
Resistance Level $4.33 $2.43
Average True Range (ATR) 0.14 0.12
MACD 0.04 0.00
Stochastic Oscillator 80.62 53.33

Price Performance

Historical Comparison
III
ABOS

About III Information Services Group Inc.

Information Services Group Inc is an AI-centered technology research and advisory firm providing digital transformation and technology advisory services that help organizations optimize performance, reduce costs, and accelerate innovation. The Company's expertise includes sourcing advisory, cloud and data analytics, managed governance and risk services, network and software advisory, technology strategy and operations design, change management, and market intelligence, serving both private- and public-sector clients globally. It operates in one segment, fact-based sourcing advisory services, and operates principally in the Americas, with generate maximum revenue in Europe and the Asia Pacific.

About ABOS Acumen Pharmaceuticals Inc.

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.

Share on Social Networks: